1. Home
  2. LNG vs NTRA Comparison

LNG vs NTRA Comparison

Compare LNG & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cheniere Energy Inc.

LNG

Cheniere Energy Inc.

HOLD

Current Price

$298.82

Market Cap

55.5B

Sector

Utilities

ML Signal

HOLD

Logo Natera Inc.

NTRA

Natera Inc.

HOLD

Current Price

$402.25

Market Cap

56.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LNG
NTRA
Founded
1983
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Oil/Gas Transmission
Medical Specialities
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
55.5B
56.7B
IPO Year
1996
2015

Fundamental Metrics

Financial Performance
Metric
LNG
NTRA
Price
$298.82
$402.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
22
23
Target Price
$313.00
★ $403.89
AVG Volume (30 Days)
1.4M
★ 1.5M
Earning Date
10-29-2026
11-05-2026
Dividend Yield
★ 0.77%
N/A
EPS Growth
★ 69.93
0.65
EPS
N/A
★ N/A
Revenue
★ $19,976,000,000.00
$210,939,000.00
Revenue This Year
$16.18
$26.19
Revenue Next Year
$3.31
$20.84
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 27.21
N/A
52 Week Low
$186.20
$181.00
52 Week High
$300.94
$437.41

Technical Indicators

Market Signals
Indicator
LNG
NTRA
Relative Strength Index (RSI) 67.71 56.53
Support Level $250.03 $380.39
Resistance Level $299.87 $437.41
Average True Range (ATR) 7.08 18.93
MACD 1.63 -2.67
Stochastic Oscillator 98.77 39.34

Price Performance

Historical Comparison
LNG
NTRA

About LNG Cheniere Energy Inc.

Cheniere Energy is a liquefied natural gas producer with two facilities in Corpus Christi, Texas, and Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. A subsidiary, Cheniere Energy Partners, owns the Sabine Pass facility and trades as a master limited partnership.

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

Share on Social Networks: